Kancera AB logo

KAN - Kancera AB Share Price

SEK13.02 -0.2  -1.8%

Last Trade - 3:24pm

Small Cap
Market Cap £62.7m
Enterprise Value £58.1m
Revenue £7.63k
Position in Universe 1026th / 1832
Unlock KAN Revenue
Relative Strength (%)
1m -31.9%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -69.0%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
0.28 0.31 0.11 0.36 3.22 0.090 -20.4%
Balance Sheet
FINANCIAL BRIEF: : For the fiscal year ended 31 December 2020, KanceraAB revenues decreased 97% to SEK90K. Net loss increased 32%to SEK47.6M. Revenues reflect a decrease in demand for theCompany's products and services due to unfavorable marketconditions. Higher net loss reflects Administrativeexpenses increase from SEK5.4M to SEK11.7M (expense), R&DExpenses increase of 14% to SEK39.3M (expense), IE onCapital Financing increase from SEK97K to SEK1M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for KAN
Graphical History


KAN Revenue Unlock KAN Revenue

Net Income

KAN Net Income Unlock KAN Revenue

Normalised EPS

KAN Normalised EPS Unlock KAN Revenue

PE Ratio Range

KAN PE Ratio Range Unlock KAN Revenue

Dividend Yield Range

KAN Dividend Yield Range Unlock KAN Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
KAN EPS Forecasts Unlock KAN Revenue
Profile Summary

Kancera AB is a Sweden-based company that develops and sells drug candidates in the field of cancer. The Company's activities are divided into two areas, namely Pharmaceutical Development and Industrial Research and Development (R&D). Pharmaceutical Development area runs such projects, as Project PFKFB3, which aims to develop a drug to combat solid tumors; and Project ROR-1, which aims to develop a drug to combat chronic lymphatic leukemia (CLL). Industrial R&D area consists of the identification of new projects of high potential and of R&D work commissioned by clients. The Company's other activities include development of cancer models and stem cell-based techniques. The Company is active through its subsidiary iNovacia, which carries out analytical development, as well as the identification, validation and further optimization of drug candidates. The Company's operations are conducted at the Karolinska Institutet Science Park in Solna, Sweden.

Last Annual December 31st, 2020
Last Interim December 31st, 2020
Public Since February 21, 2011
No. of Shareholders: 23,000
No. of Employees: 8
Sector Healthcare
Industry Biotechnology & Medical Research
Exchange OMX Nordic Exchange Stockholm
Shares in Issue 55,771,963
Free Float (0.0%)
Eligible for
KAN Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for KAN
Upcoming Events for KAN
Friday 21st May, 2021
Q1 2021 Kancera AB Earnings Release
Friday 20th August, 2021
Q2 2021 Kancera AB Earnings Release
Frequently Asked Questions for Kancera AB
What is the Kancera AB share price?

As of 3:24pm, shares in Kancera AB are trading at SEK13.02, giving the company a market capitalisation of £62.7m. This share price information is delayed by 15 minutes.

How has the Kancera AB share price performed this year?

Shares in Kancera AB are currently trading at SEK13.02 and the price has moved by 55.87% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Kancera AB price has moved by 18.2% over the past year.

What are the analyst and broker recommendations for Kancera AB?

Of the analysts with advisory recommendations for Kancera AB, there are there are currently "buy" , "hold" and "sell" recommendations. The overall consensus recommendation for Kancera AB is Not available. You can view the full broker recommendation list by unlocking its StockReport.

When will Kancera AB next release its financial results?

Kancera AB is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the Kancera AB dividend yield?

Kancera AB does not currently pay a dividend.

Does Kancera AB pay a dividend?

Kancera AB does not currently pay a dividend.

When does Kancera AB next pay dividends?

Kancera AB does not currently pay a dividend.

How do I buy Kancera AB shares?

To buy shares in Kancera AB you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Kancera AB?

Shares in Kancera AB are currently trading at SEK13.02, giving the company a market capitalisation of £62.7m.

Where are Kancera AB shares listed? Where are Kancera AB shares listed?

Here are the trading details for Kancera AB:

Country of listing: Sweden
Exchange: STO
Ticker Symbol: KAN
What kind of share is Kancera AB?

Based on an overall assessment of its quality, value and momentum, Kancera AB is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Kancera AB share price forecast 2021?

Shares in Kancera AB are currently priced at SEK13.02. At that level they are trading at 90.95% premium to the analyst consensus target price of 0.00.

How can I tell whether the Kancera AB share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Kancera AB. Over the past six months, the relative strength of its shares against the market has been -53.92%. At the current price of SEK13.02, shares in Kancera AB are trading at -41.8% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Kancera AB PE Ratio?

We were not able to find PE ratio data for Kancera AB.

Who are the key directors of Kancera AB?

Kancera AB's management team is headed by:

Erik Nerpin - CHM
Hakan Mellstedt - DRC
Thomas Olin - CEO
Martin Norin - COO
Carl-Henrik Heldin - DRC
Charlotte Edenius - DRC
Joachim Forsgren - MGB
Anders Gabrielsen - DRC
Who are the major shareholders of Kancera AB?

Here are the top five shareholders of Kancera AB based on the size of their shareholding:

State Street Global Advisors (US) Investment Advisor/Hedge Fund
Percentage owned: 0.37% (205k shares)
SPDR Portfolio World ex-US ETF Mutual Fund
Percentage owned: 0.31% (173k shares)
SPDR S&P International Small Cap ETF Mutual Fund
Percentage owned: 0.06% (32.6k shares)
Similar to KAN
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.